

Effects of Caffeine Administration on Brain Sodium-Potassium ATPase Activity in Healthy and Streptozotocin-Induced Diabetic Female Wistar Rats

Aminat Omolola Imam-Fulani, BSc, MSc,
Olawumi Kikelomo Bamikole, BSc, and Bamidele Victor Owoyele, BSc, MSc, PhD

Background: Diabetes mellitus affects the morphology and plasticity of the brain, leading to cognitive and electrophysiological impairment. We aim to determine effects of caffeine on brain Na^+/K^+ -ATPase activity in streptozotocin-induced diabetic female rats.

Methods: Female Wistar rats weighing about 180–200 g were used for the study and were divided into three study groups. Study groups A 1, 2, 3 were healthy rats administered 15, 20, 25 mg/kg caffeine intraperitoneally (i.p), respectively, for 5 weeks; study groups B 1, 2, 3 administered 15, 20, 25 mg/kg caffeine (i.p), respectively, for 5 weeks and maintained on caffeine for 3 weeks after diabetes induction; study groups C 1, 2, 3, were diabetic rats administered 15, 20, 25 mg/kg caffeine (i.p), respectively, for 3 weeks; control and diabetic untreated were administered normal saline. After administration, brains were homogenized in sucrose solution and kept at 4°C. Enzyme assay was conducted.

Results: A significant ($p < 0.05$) decrease in Na^+/K^+ -ATPase activity of diabetic untreated (250.9 ± 0.26) when compared with control (415.6 ± 0.26). Study groups A 1, 2, 3 showed an increase in Na^+/K^+ -ATPase activities (1022.0 ± 0.51 , 825.0 ± 0.22 , 498.6 ± 0.04 , respectively). Study groups B 1 and 3 showed a significant decrease in Na^+/K^+ -ATPase activities (280.0 ± 0.40 and 232.4 ± 0.34 , respectively) when compared with control and a significant increase in group 2 (374.0 ± 0.34) when compared with diabetic group. Diabetic rats in study C (groups 1, 2, 3) showed an increase in Na^+/K^+ -ATPase activities (468.8 ± 0.51 , 428.5 ± 0.50 , and 259.9 ± 0.20 , respectively) when compared with diabetic untreated.

Conclusion: This study shows that caffeine at low to moderate doses improves the brain Na^+/K^+ -ATPase activities in diabetic rats.

Introduction

DIABETES MELLITUS (DM), commonly referred to as diabetes, is a group of metabolic diseases in which there is high blood sugar levels over a prolonged period. This is due to either the pancreas not producing enough insulin or because cells of the body do not respond properly to the insulin that is produced.¹ There are three main types of DM.² Type I DM is characterized by loss of the insulin-producing beta cells of the islets of Langerhans in the pancreas, leading to insulin deficiency. This type can further be classified as immune mediated or idiopathic. The majority of type 1 diabetes is of the immune-mediated nature, in which beta cell loss is a T-cell-mediated autoimmune attack.³ Type 2 DM is the most common type

characterized by insulin resistance, which may be combined with relatively reduced insulin secretion.¹ The defective responsiveness of body tissues to insulin is believed to involve the insulin receptor. However, the specific defects are not known. This is due primarily to lifestyle factors and genetics.⁴ Gestational diabetes mellitus (GDM) is defined by glucose intolerance of variable severity with onset of first recognition during pregnancy.⁵ Hyperglycemia during pregnancy is found to be associated with various maternal and perinatal adverse outcomes.⁶

The cause of diabetes depends on the type. Type 2 diabetes is due primarily to lifestyle factors and genetics.⁴ Type 1 diabetes is also partly inherited and then triggered by certain infections, with some evidence pointing at

Coxsackie B4 virus. If the amount of insulin available is insufficient, the cells respond poorly to the effects of insulin (insulin insensitivity or resistance), or if the insulin itself is defective, then glucose will not have its usual effect, so it will not be absorbed properly by the body cells that require it, nor will it be stored appropriately in the liver and muscles. The net effect is persistent high levels of blood glucose, poor protein synthesis, and other metabolic derangements, such as acidosis.

The classical symptoms of diabetes are polyuria (frequent urination), polydipsia (increased thirst), and polyphagia (increased hunger).⁷ Symptoms may develop rapidly (weeks or months) in type 1 diabetes, while in type 2 diabetes they usually develop much more slowly and may be subtle or absent.

DM affects the morphology and plasticity of the brain, causing cognitive, memory, and electrophysiological impairment. Diabetes often leads to complications such as retinopathy, peripheral neuropathy, and stroke.⁸ There is evidence signifying that type 1 and type 2 diabetes can cause complications within the central nervous system (CNS).^{9,10} Manifestations of diabetes-induced CNS complications may include structural alterations or brain atrophy, as well as changes in electrophysiological features that ultimately result in deficits in cognitive activity.¹¹ Dysfunctional regulation of glucose elicits neuronal synaptic reorganization¹² and increased proliferation of astrocytes¹³ in the hippocampus of streptozotocin (STZ)-induced diabetic rodents, an experimental model of type 1 diabetes.

When blood sugar levels start to climb in diabetes, a number of body systems are affected and that includes the brain, since studies have linked diabetes with a higher risk of stroke and dementia. A new study¹⁴ reported that changes in blood vessel activity in the brains of diabetics may lead to drops in cognitive functions and their ability to perform daily activities.

From studies performed in adults with type 1 diabetes, reductions in measures of motor speed and psychomotor efficiency can be seen in patients in midlife.¹⁵ These neurocognitive changes have been associated with a reduction in white matter volume or alteration in white matter histology in some^{16,17} but not all^{18,19} investigations. Reduction in gray matter density in brain regions responsible for language processing and memory¹⁹ and generalized atrophy²⁰ have also been identified in young adults with long-standing type 1 diabetes. Patients with chronic hyperglycemia,²¹ early onset of disease,²² or recurrent severe hypoglycemia²³ appear to be at particular risk for the development of changes in brain structure and function over time, although these associations have not been consistently observed in all groups of subjects with type 1 diabetes who have been investigated.^{18,19}

Also, glucose and insulin are both instrumental regulators of cognitive function,^{24–27} further supporting the hypothesis that improper regulation of these two factors may contribute to cognitive deficits in diabetes.^{24–29}

Caffeine is the common name for 1,3,7-trimethylxanthine, which was derived from the German word *kaffee* and the French word *café*, each meaning coffee.³⁰ It is a naturally occurring alkaloid that is found in varying quantities in the beans, leaves, and fruits of more than 60 plants. Some common sources of caffeine are the kola nut (*Cola acuminata*), cacao bean (*Theobroma cacao*), yerba mate (*Ilex paraguariensis*), and guarana berries (*Paullinia cupana*); however, roasted coffee beans (*Coffea Arabica* and *Coffea robusta*) and tea leaves (*Camellia sinensis*) are the world's primary sources of dietary caffeine.³¹

Caffeine has been widely studied in a variety of areas regarding human health and performance.³² Many studies confirm caffeine's ability to enhance mood and alertness,^{33,34} exercise performance,³⁴ the speed at which information is processed, awareness, attention, and reaction time.³⁶ In addition, research has suggested that caffeine can aid in reducing symptoms associated with Parkinson's disease (PD) such as the deterioration of gross and small motor skills and tremors.^{37,38} Since PD is a neurodegenerative disease that results in progressive loss of dopaminergic neurons of the substantia nigra, caffeine a nonselective adenosine antagonist is thought to aid in improving the performance of the dopaminergic system by blocking the AA_2 receptors, thus stimulating dopamine release.³⁸

The relationship between caffeine and DM has been a controversial topic among scientists. However, caffeine has been reported to have both positive and negative effects on DM. Caffeine consumption has been associated with a lower risk of DM type 2. The majority of the studies on this topic were done on coffee. Test results indicate that consumers who drink at least three or more cups of either caffeinated or decaffeinated coffee every day show a decrease in the risk of type 2 diabetes. In Japan, a study was done to examine the relationship between consumption of green, black, and oolong teas and the risk of diabetes; and it was found that caffeine containing beverages were associated with a decreased risk of type II diabetes.³⁹

Caffeine acts as an antagonist of adenosine A_1 and A_{2A} receptor at a nontoxic dose.⁴⁰ Caffeine consumption has been reported to alleviate cognitive impairment in both humans and animals.^{41,42}

STZ-induced diabetes modifies the expression and density of adenosine receptors in the hippocampus⁴³ and also reduced the sodium-potassium ATPase (Na^+/K^+ -ATPase) in the brain.⁴⁴

Na^+/K^+ -ATPase (sodium-potassium adenosine triphosphatase, also known as Na^+/K^+ pump, sodium-potassium pump, or sodium pump) is an antiporter-like enzyme (an electrogenic transmembrane ATPase) located in the plasma membrane of all animal cells.

Na^+/K^+ -ATPase helps maintain resting potential, effect transport, and regulate cellular volume.⁴⁵ It also

functions as a signal transducer/integrator to regulate MAPK pathway, ROS, as well as intracellular calcium. In most animal cells, Na^+/K^+ -ATPase is responsible for about 1/5 of the cell's energy expenditure. For neurons, Na^+/K^+ -ATPase can be responsible for up to 2/3 of the cell's energy expenditure.⁴⁶

This enzyme, found in all mammalian cell membranes, is necessary for proper cellular function since it helps to preserve the ionic gradients across the cell membrane and thus the membrane potential and osmotic equilibrium of the cell.⁴⁷ This function is crucial for cell survival and body homeostasis, which is why it is a targeted focus of this study.

Na^+/K^+ -ATPase malfunction and mutation have been implicated in renal dysfunction, hypertension, and Parkinsonism.⁴⁸

Brain Na^+/K^+ -ATPase enhances neuroprotection, memory consolidation, and diminishes cognitive deficits.⁴⁹

Diabetes has a marked effect on the metabolism of a variety of tissues and because the Na^+/K^+ -ATPase is critical for the membrane potential and many transports, a change in its activity in diabetes would have a profound consequence in these tissues.⁵⁰

Among the diabetes-induced metabolic changes, disturbances of Na^+/K^+ -ATPase activity have been widely reported.⁵¹ Das and colleagues⁵² first described a decrease of this enzyme activity in the sciatic nerve of diabetic rat, whereas an increase in enzyme activity was found in mucosa of the small intestine of diabetic rat.⁵³ These two examples illustrate the different effects of diabetes on Na^+/K^+ -ATPase depending on the tissues. Thus, it has been observed that the brain Na^+/K^+ -ATPase activity is reduced in the diabetic state in male animals.⁴⁴

However, it has been reported⁵⁴ that female and male brains differ. The differences begin early during development due to the combination of genetic and hormonal events and continue throughout the life span of an individual. They further emphasized that female reproductive status has to be taken into account when studying sex differences in health and disease susceptibility, in the pharmacological effects of drugs, and in the study of brain and behavior.

Physiological sex differences account for marked differences in disease incidence, manifestation, prognosis, and treatment observed between the sexes. Differences in disease susceptibility, time of onset of symptoms, and drug response have become evident in diseases such as cancer, obesity, coronary heart disease, autoimmune and mental health disorders, among others.⁵⁵ This report highlights the need to conduct hypothesis-driven biomedical studies that take into account sex as a basic human variable. The report also validates the need for research on sex-based differences at the molecular, cellular, and whole organism levels and at different stages of the life span. Also, it further recommends the

use of animal models that best mimic conditions being addressed.⁵⁵

Since previous studies were carried out on male rodents treated after induction of diabetes with a specific dose of caffeine, we therefore aim to determine the effects of caffeine (an adenosine receptor antagonist) on brain Na^+/K^+ -ATPase activity in STZ-induced diabetic female rats, considering exposure to caffeine treatment before induction of diabetes and maintained on treatment after induction of diabetes.

Materials and Methods

Experimental animals

Female Wistar rats, aged 12–13 weeks old and weighing about 180–200g, were used for the study. The animals were obtained from the Biochemistry Department University of Ilorin, Ilorin. The rats were maintained, with free access to food (rat pellet) and water, with a 12-hour light/12-hour dark cycle (lights on at 07:00 hour). Rats were used in accordance with the rules for the Care and Use of Laboratory Animals and the research was approved by the Ethics Committee of the University of Ilorin, Ilorin, Nigeria.

Study design

Eleven groups of seven female Wistar rats each were used for the study. Study groups A 1, 2, and 3 were healthy rats administered 15, 20, and 25 mg/kg caffeine intraperitoneally (i.p) per day, respectively, for 5 weeks; study groups B 1, 2, and 3 were healthy rats administered 15, 20, and 25 mg/kg caffeine (i.p) per day, respectively, for 5 weeks and were maintained on caffeine for 3 weeks after induction of diabetes; study groups C 1, 2, and 3 were diabetic rats placed on caffeine immediately after induction of DM at 15, 20, and 25 mg/kg (i.p) per day, respectively, for 3 weeks; the control and diabetic untreated group was administered normal saline.

Induction of diabetes

Type 1 diabetes was induced with freshly prepared 50 mg/kg STZ (in citrate buffer 0.1 M, pH 4.5), which induced sustained hyperglycemia after 3 days.⁵⁶ Dextrose saline was given after induction for rehydration. Food and water intake was closely monitored after induction. The animals were confirmed diabetic by the measurement of fasting blood glucose in the tail vein blood after 72 hours of injection with a portable glucometer (on-call plus). The animals with hyperglycemia (blood glucose >8.1 mM) and stable symptoms of DM such as polyuria and polydipsia were used for the study.

Glycemia assessment

Before glucose level estimation, the rats underwent 12 hours of overnight fasting as described previously.⁵⁷

After fasting, to determine baseline glucose levels, blood samples (0.1 μ L) were collected from the distal end of the tail and analyzed immediately using an On-Call® Plus glucometer with the corresponding On-Call Plus test strips (Roche, Mannheim, Germany).

Caffeine dose and administration

Caffeine (Sigma-Aldrich, St. Louis, MO) was administered intraperitoneally. Doses of 15, 20, and 25 mg/Kg (BW)/day were given to specified groups.

Preparation of brain homogenate

At the end of the administration, animals were anesthetized, the brains were promptly removed, weighed, and homogenized in an ice-cold sucrose isotonic buffer solution. Crude homogenates were initially centrifuged at 1000 rpm for 10 minutes. The supernatant obtained was centrifuged again at 25,000 rpm for 3 minutes to obtain the mitochondrial pellet. The pellet was washed three times by resuspending it in the homogenizing buffer medium (pH 7.4). All the centrifugation steps were carried out at 4°C in an H1850R tabletop high-speed refrigerated centrifuge. Mitochondria-contained solutions were kept below 4°C for enzyme estimation. Protein determination and assay for the enzyme were carried out within 24 hours of sample collection. Na^+/K^+ -ATPase activities were expressed as $\mu\text{molPi}/\text{mg protein}/\text{hour} \times 10^{-3}$.

Na^+/K^+ -ATPase assay

Na^+/K^+ -ATPase assay was measured according to the method described by Akagawa and Tsukada.⁵⁸ The reaction mixture (1 mL) contains 200 mM NaCl, 40 mM KCl, 60 mM Tris (pH 7.4), 80 mM $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$, 20 mM ethylene glycol-bis (2 aminoethylether) tetraacetic acid (EGTA), enzyme source, 8 mM ATP, after which it was incubated for 1 hour at 37°C. The reaction was stopped by adding 5% ice-cold sodium lauryl sulfate (SLS). After which the medium was centrifuged at 1000 g for 10 minutes. Inorganic phosphate produced in the supernatant was determined by the method of Fiske and Subbarow.⁵⁹ Protein determination was carried out according to the method of Lowry *et al.*⁶⁰ Na^+/K^+ -ATPase activities were expressed as $\mu\text{molPi}/\text{mg protein}/\text{hour} \times 10^{-3}$.

Statistical analyses

Statistical analyses were performed using the SPSS® statistical software, version 16.0 (SPSS, Inc., Chicago, IL) for Windows®. Data are presented as mean $\pm$ SE. Differences between continuous data were analyzed using the paired Student's *t*-test and analysis of variance using a Duncan *post hoc* comparison, as appropriate.

Results

Blood glucose level in healthy and diabetic rats

Healthy rats administered caffeine 15 mg/kg, 20 mg/kg, and 25 mg/kg showed no significant difference in the blood glucose level (4.60 ± 0.16 , 4.17 ± 0.20 , and 4.41 ± 0.07 respectively) when compared with control (4.14 ± 0.23), as shown in Figure 1. All diabetic groups showed a significant ($p < 0.05$) increase in blood glucose level when compared with control each week, but with varying glucose level changes when compared with the diabetic untreated group, as highlighted in Table 1.

Brain Na^+/K^+ -ATPase activities in healthy and diabetic rats

Table 2 shows a significant reduction in brain Na^+/K^+ -ATPase activities in diabetic rats when compared with control. The brain Na^+/K^+ -ATPase decreases from 4.16 ± 0.26 ($p < 0.05$) in control to 2.51 ± 0.26 ($p < 0.05$) in diabetic untreated group.

Caffeine and its effect on brain Na^+/K^+ -ATPase activities in normal rats

Caffeine increases the activities of brain Na^+/K^+ -ATPase, as indicated in Figure 2. There is an increase in Na^+/K^+ -ATPase activities in healthy rats administered caffeine, with 10.20 ± 0.51 , 8.25 ± 0.22 , and 4.99 ± 0.04 ($p < 0.05$) activity in study groups A 1, 2, and 3, respectively, when compared to 4.16 ± 0.26 ($p < 0.05$) in control.




FIG. 1. Blood glucose level in healthy rats administered caffeine. Values are mean $\pm$ SEM, $n = 7$, paired *t*-test $p < 0.05$. Lcaff = caffeine administration 15 mg/kg; Mcaff = caffeine administration 20 mg/kg; Hcaff = caffeine administration 25 mg/kg.

TABLE 1. EFFECT OF CAFFEINE ON THE BLOOD GLUCOSE LEVEL (MM) IN DIABETIC RATS

Groups Weeks	Control	Diabetic untreated	Caff 15 mg/kg Before/after diabetes	Caff 20 mg/kg Before/after diabetes	Caff 25 mg/kg Before/after diabetes	Caff 15 mg/kg After diabetes	Caff 20 mg/kg After diabetes	Caff 25 mg/kg After diabetes
Week 1	4.14 ± 0.21	21.82 ± 2.14 ^a	15.80 ± 1.18 ^b	22.17 ± 1.60 ^a	20.92 ± 2.09 ^a	22.36 ± 2.74 ^a	20.76 ± 1.75 ^a	22.36 ± 2.71 ^a
Week 2	5.59 ± 0.20	18.77 ± 2.69 ^a	11.80 ± 1.54 ^b	24.42 ± 1.86 ^a	19.18 ± 2.06 ^a	19.67 ± 3.15 ^a	29.31 ± 1.79 ^b	16.74 ± 2.97 ^a
Week 3	3.91 ± 0.32	19.67 ± 2.31 ^a	19.62 ± 0.73 ^a	32.22 ± 1.24 ^b	30.66 ± 1.39 ^b	21.57 ± 2.59 ^a	26.13 ± 1.67 ^b	22.33 ± 3.61 ^a

Values are mean ± SEM, $n = 7$.

^a $p < 0.05$ compared with control group.

^b $p < 0.05$ compared with control and diabetic untreated group.

Caff, Caffeine treatment.

TABLE 2. EFFECT OF UNTREATED DIABETES ON BRAIN Na^+/K^+ -ATPase Activity

Groups	Na^+/K^+ -ATPase activity ($\mu\text{molPi}/\text{mg protein}/\text{hour} \times 10^{-3}$)
Control	415.6 ± 0.26
Diabetic untreated	250.9 ± 0.26 ^a

Values are mean ± SEM, $n = 7$.

^a $p < 0.05$ compared with control group.

Caffeine and its effect on brain Na^+/K^+ -ATPase activities in diabetic rats

Study groups B 1, 2, and 3 rats administered caffeine before inducing diabetes and also maintained on caffeine after inducing diabetes show reduced activities 2.80 ± 0.40 , 3.74 ± 0.34 , and 2.32 ± 0.34 ($p < 0.05$), respectively, when compared to control 4.16 ± 0.26 ($p < 0.05$), with significant reduction in groups 1 and 3. Groups 1 and 2 show an increase in brain Na^+/K^+ -ATPase activities (2.80 ± 0.40 and 3.74 ± 0.34 ($p < 0.05$), respectively) when compared to diabetic untreated group activity [2.51 ± 0.26 ($p < 0.05$)], and only group 2 [3.74 ± 0.34 ($p < 0.05$)] was significantly different from the diabetic group [2.51 ± 0.26 ($p < 0.05$)], as shown in Figure 3.

Also, rats placed on caffeine treatment only after induction of diabetes (study groups C 1, 2, and 3), as shown in Figure 4, showed an increase in Na^+/K^+ -ATPase activities [4.67 ± 0.51 , 4.29 ± 0.50 , and 2.60 ± 0.20 ($p < 0.05$)] when compared with the diabetic group [2.51 ± 0.26 ($p < 0.05$)], with a significant increase ($p < 0.05$) in groups 7 and 8.

Discussion and Conclusion

A series of studies^{61–63} have been conducted on the effect of caffeine on blood glucose level with varying views, and this study shows that caffeine has no effect on blood glucose level in healthy rats but may lead to either an




FIG. 2. Brain Na^+/K^+ -ATPase activity in study groups A (healthy rats administered caffeine). Values are mean ± SEM, $n = 7$, paired t -test * $p < 0.05$ compared with control group. CAFF, caffeine administration.




FIG. 3. Brain Na⁺/K⁺-ATPase activity in study groups B (rats administered caffeine before and maintained on caffeine after induction of diabetes). Values are mean $\pm$ SEM, $n=7$, ANOVA ($p<0.05$) and Dunn's *post hoc* test, bars with different letters are significantly different, $p<0.05$.

increase or decrease in blood glucose in the diabetic state depending on doses and periods of exposure.

Cognitive dysfunction and dementia have recently been proven to be common and underrecognized complications of DM.⁶⁴ This study shows that brain Na⁺/K⁺-ATPase activity is altered in the diabetic state as previously reported^{44,65-67} and has also been able to confirm as such in female rats since most of the previous studies are based on the use of male rodents. The reduced activity is associated with the cognitive and memory impairment observed in diabetic state because the Na⁺/K⁺-

ATPase is known to be a key enzyme involved in the maintenance of ionic gradient of Na⁺ and K⁺ and in the maintenance of action potential and resting membrane potential.⁶⁸ Therefore, alteration in the enzyme activity may be an important factor in the pathogenesis of metabolic complications observed in the CNS in diabetic state.⁶⁹ Also, the reduced activity can be directly linked to the observations by Chung *et al.*,¹⁴ who reported diminished global and regional cerebral vasoreactivity and a decline in multiple cognitive tasks in diabetes due to inflammation.

This study also shows that caffeine increases the brain Na⁺/K⁺-ATPase activities in normal rats as indicated in Figure 2. This agrees with the work of Obochi *et al.*,⁷⁰ which revealed that kola nut and caffeine independently produced an increase in brain Na⁺/K⁺-ATPase activities.³⁵ However, there is paucity of information on the effect of caffeine on brain Na⁺/K⁺-ATPase activity in diabetic state, and this study shows that treatment with caffeine shows promising effect on increasing brain Na⁺/K⁺-ATPase activity in diabetics (Figs. 3 and 4). Naiara *et al.*⁶⁷ also reported a decrease in the cerebral cortex Na⁺/K⁺-ATPase in diabetic rats and reported that the observed reduction may result from both glycosylation in the b subunit of this enzyme and destabilization of plasmatic membrane by reactive species. They further reported an increase in Na⁺/K⁺-ATPase activity basically in the cerebral cortex of diabetic rats after treatment with caffeine. Although previous studies^{67,69} made use of male rodents, this study considered female Wistar rats to rule out gender influence.

Caffeine is commonly consumed in different beverages and soft drinks in the society, since no report has been given to pretreatment of caffeine before diabetes onset, this study considered the effect/influence of caffeine intake before diabetic onset in study groups B (prediabetic treatment, Fig. 3), as opposed to postdiabetic treatment with caffeine, previously reported.⁶⁷ In this study, caffeine at a dose of 20 mg/kg restores Na⁺/K⁺-ATPase activity to normal, while in study groups C (postdiabetic treatment), caffeine at a dose of 15 and 20 mg/kg restores Na⁺/K⁺-ATPase activity to normal. This observation is due to caffeine tolerance in study groups B, and thus, it is this study group that majorly mimics the societal focus.

This study further evaluates different doses of caffeine treatment unlike the previous studies.^{67,69} The highest dose of caffeine used in this study (25 mg/kg BW) shows very little or no effect on brain Na⁺/K⁺-ATPase activity both in healthy groups and pre/postexposure to caffeine in the diabetic groups and, as such, may be due to poor adaptation to the high dose of caffeine.

However, the observed improvement of brain Na⁺/K⁺-ATPase activity in diabetic states may be a linking factor with the findings of Duarte *et al.*,⁵⁶ who reported that caffeine prevents diabetes-induced memory impairment and synaptotoxicity in the hippocampus of diabetic mice.




FIG. 4. Brain Na⁺/K⁺-ATPase activity in study groups C (diabetic rats administered caffeine). Values are mean $\pm$ SEM, $n=7$, ANOVA ($p<0.05$) and Dunn's *post hoc* test, bars with different letters are significantly different, $p<0.05$.

Hence, the current study shows that brain Na^+/K^+ -ATPase activity is reduced in STZ-induced diabetic female Wistar rats. The brain Na^+/K^+ -ATPase activity dysfunction has been implicated in electrophysiological abnormalities thus leading to poor excitation, cerebral vasoreactivity, poor nutrient delivery, and declined cognition. The result has also demonstrated the potential of caffeine to reverse brain Na^+/K^+ -ATPase activity deficit in the diabetic state.

Therefore, more researches should be carried out to further unravel the mechanism of action of caffeine and its consequential effects on brain Na^+/K^+ -ATPase. This can be a promising focus of coadjuvant treatment in ameliorating some of the CNS disorders resulting from complications of diabetes.

Acknowledgments

We acknowledge the contribution and guidance of Dr. Adedoyin Igunnu of Biochemistry Department, University of Ilorin, Nigeria. We also acknowledge the contribution of Mr Wahab Imam Abdulmajeed of Physiology Department, University of Ilorin, Nigeria. Also, the contribution of the following graduates Alabi John, Ariyo Stephen, Alaye Emmanuel, and Atta Aisha during training as undergraduate students in the Department of Physiology, University of Ilorin, cannot be over looked.

Author Disclosure Statement

No competing financial interests exist.

References

- David GG, Dolores S. *Greenspan's Basic & Clinical Endocrinology*. New York: McGraw-Hill Medical; 2011; 9:17.
- WHO "Diabetes Fact sheet N°312". World Health Organization. Diabetes, Diabetes Fact Sheet October 2013; 312:1.
- Rother K. Diabetes treatment—bridging the divide. *N Engl J Med*. 2007;356:1499–1501.
- Risérus U, Willet W. Dietary fats and prevention of type 2 diabetes. *Prog Lipid Res*. 2009;48:44–51.
- World Health Organization. Diagnostic Criteria and Classification of hyperglycaemia first detected in pregnancy. 2013. Report Number: WHO/NMH/MND/13.2.
- Landon MB, Mele L, Spong CY, Carpenter MW, Ramin SM, *et al*. The relationship between maternal glycemia and perinatal outcome. *Obstet Gynecol*. 2011;117:218–224.
- Cooke DW, Plotnick L. "Type 1 diabetes mellitus in pediatrics". *Pediatr Rev*. 2008;29:374–384.
- The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes-mellitus. *N Eng J Med*. 1993;329:977–986.
- McCall AL. Perspectives in Diabetes. The Impact of Diabetes on the CNS. *Diabetes*. 1992;41:557–570.
- Shayna AW, Gerardo GP, Claudia AG, Lawrence PR. A look inside the diabetic brain: Contributors to diabetes-induced brain aging. *Biochim Biophys Acta*. 2009;1792:444–453.
- Gispén WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. *Trends Neurosci*. 2000;23:542–549.
- Magarinos AM, McEwen BS. Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. *Proc Natl Acad Sci USA*. 2000;97:11056–11061.
- Saravia FE, Revsin Y, Gonzalez Deniselle MC, Gonzalez SL, Roig P, Lima A, Homo-Delarche F, De Nicola AF. Increased astrocyte reactivity in the hippocampus of murine models of type 1 diabetes: The nonobese diabetic (NOD) and streptozotocin-treated mice. *Brain Res*. 2002;957:345–353.
- Chung C, Pimentel D, Jor'dan AJ, Hao Y, Milberg W, Novak V. Inflammation-associated declines in cerebral vasoreactivity and cognition in type 2 diabetes. *Neurology*. 2015;85:450–458.
- Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Harth J. Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. *N Engl J Med*. 2007;356:1842–1852.
- Kodl CT, Franc DT, Rao JP, Anderson FS, Thomas W, Mueller BA, Lim KO, Seaquist ER. Diffusion tensor imaging identifies deficits in white matter microstructure in subjects with type 1 diabetes that correlate with reduced neurocognitive function. *Diabetes*. 2008;7:3083–3089.
- Wessels AM, Rombouts SA, Remijnse PL, Boom Y, Scheltens P, Barkhof F, Heine RJ, Snoek FJ. Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume. *Diabetologia*. 2007;50:1763–1769.
- Brands AM, Kessels RP, Hoogma RP, Henselmans JM, van der Beek Boter JW, Kappelle LJ, de Haan EH, Biessels GJ. Cognitive performance, psychological well-being, and brain magnetic resonance imaging in older patients with type 1 diabetes. *Diabetes*. 2006;55:1800–1806.
- Musen G, Lyoo IK, Sparks CR, Weinger K, Hwang J, Ryan CM, Jimerson DC, Hennen J, Renshaw PF, Jacobson AM. Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. *Diabetes*. 2006;55:326–333.
- Lobnig BM, Krömeke O, Optenhostert-Porst C, Wolf OT. Hippocampal volume and cognitive performance in long-standing type 1 diabetic patients without macrovascular complications. *Diabet Med*. 2006;23:32–39.
- Ferguson SC, Blane A, Perros P, McCrimmon RJ, Best JJ, Wardlaw J, Deary IJ, Frier BM. Cognitive ability and brain structure in type 1 diabetes: Relation to microangiopathy and preceding severe hypoglycemia. *Diabetes*. 2003;52:149–156.
- Ferguson SC, Blane A, Wardlaw J, Frier BM, Perros P, McCrimmon RJ, Deary IJ. Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function. *Diabetes Care*. 2005;28:1431–1437.
- Northam EA, Rankins D, Lin A, Wellard RM, Pell GS, Finch SJ, Werther GA, Cameron FJ. Central nervous system function in youth with type 1 diabetes 12 years after disease onset. *Diabetes Care*. 2009;32:445–450.

24. Hall JL, Gonder-Frederick LA, Chewning WW, Silveira J, Gold PE. Glucose enhancement of performance on memory tests in young and aged humans. *Neuropsychologia*. 1989;27:1129–1138.
25. McNay EC, Fries TM, Gold PE. Decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand during a spatial task. *Proc Natl Acad Sci USA*. 2000;97:2881–2885.
26. McNay EC, McCarty RC, Gold PE. Fluctuations in brain glucose concentration during behavioral testing: Dissociations between brain areas and between brain and blood. *Neurobiol Learn Mem*. 2001;75:325–337.
27. Benedict C, Hallschmid M, Schultes B, Born J, Kern W. Intranasal insulin to improve memory function in humans. *Neuroendocrinology*. 2007;86:136–142.
28. Greenwood CE, Winocur G. Glucose treatment reduces memory deficits in young adult rats fed high-fat diets. *Neurobiol Learn Mem*. 2001;75:179–189.
29. Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH. Ageing and diabetes: Implications for brain function. *Eur J Pharmacol*. 2002;441:1–14.
30. Arab JB, Blumberg L. Introduction to the proceedings of the fourth international scientific symposium on tea and human health. *J Nutr*. 2008;138:1526–1528.
31. Barone JJ, Roberts HR. Caffeine consumption. *Food Chem Toxicol*. 1996;34:119–129.
32. Smit HJ, Rogers PJ. Effects of energy drinks on mood and mental performance: Critical methodology. *Food Qual Pref*. 2002;13:317–326.
33. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, Shader RI. Dose dependent pharmacokinetics and psychomotor effects of caffeine in humans. *J Clin Pharmacol*. 1997;37:693–703.
34. Lorist M, Tops MM. Caffeine, fatigue and cognition. *Brain Cogn*. 2003;53:82–94.
35. Doherty M, Smith PM. Effects of caffeine ingestion on exercise testing: A meta-analysis. *Intn J Sport Nutr Exerc Metab*. 2004;14:626–646.
36. Cysneiros RM, Farkas D, Harmatz JS, von Moltke LL, Greenblatt DJ. Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. *Clin Pharmacol Ther*. 2007;82:54–62.
37. Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. *Exp Neurobiol*. 2000;62:63–88.
38. Trevitt J, Kawa K, Jalali A, Larsen C. Differential effects of adenosine antagonists in two models of parkinsonian tremor. *Pharmacol Biochem Behav*. 2009;94:24–29.
39. Iso H, Date C, Wakai K, Fukui M, Tamakoshi A. Jacc Study Group. The relationship between green tea and total caffeine intake and risk for self-reported. *Ann Intern Med*. 2006;144:554–562.
40. BB Fredholm, JF Chen, RA Cunha, P Svenningsson, JM Vaugois. Adenosine and brain function. *Int Rev Neurobiol*. 2005;63:191–270.
41. Takahashi RN, Pamplona FA, Prediger RD. Adenosine receptor antagonists for cognitive dysfunction: A review of animal studies. *Front Biosci*. 2008;13:2614–2632.
42. Cunha RA, Agostinho PM. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. *J Alzheimer Dis*. 2010;20:95–116.
43. Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR. Adenosine A_{2A} receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. *Prog Neurobiol*. 2007;83:310–331.
44. Leong SF, Leung TK. Diabetes induced by streptozotocin causes reduced Na-K ATPase in the brain. *Neurochem Res*. 1991;16:1161–1165.
45. Hall JE, Guyton AC. *Textbook of Medical Physiology*. St. Louis, Mo: Elsevier Saunders; 2006.
46. Howarth C, Gleeson P, Attwell D. “Updated energy budgets for neural computation in the neocortex and cerebellum”. *J Cereb Blood Flow Metab*. 2012;32:1222–1232.
47. Skou JC, Esmann M. The Na,K-ATPase. *J Bioenerg Biomembr*. 1992;24:249–261.
48. Elizabeth LL, Baksho K, John NL, Jerry BL. Ouabain-Sensitive α 1 Na,K-ATPase Enhances Natriuretic Response to Saline Load. *J Am Soc Nephrol*. 2008;19:1947–1954.
49. Michael DF. The sodium-potassium pump is an information processing element in brain computation. *Front Physiol*. 2014;5:472.
50. Gupta DK, Ahmad F, Suhail M. Electrophoretic analysis of polypeptides and glycopeptides of erythrocyte membrane sampled from rats simulating mild insulin dependent diabetes mellitus. *Indian J Exp Biol*. 1998;36:934–937.
51. Sima A, Sugimoto K. Experimental diabetic neuropathy: An update. *Diabetologia*. 1999;42:773–788.
52. Das PK, Bray GM, Aguayo AJ, Rasminsky M. Diminished ouabain-sensitive, sodium-potassium ATPase activity in sciatic nerves of rats with streptozotocin-induced diabetes. *Exp Neurol*. 1976;53:285–288.
53. Gnanaprakasam M, Srivastava L. Effect of starvation, alloxan diabetes and adrenalectomy on Na⁺ K⁺ ATPase of the mucosa of the small intestine of rat. *Biochem Exp Biol*. 1978;14:257–262.
54. Jill BB, Arthur PA, Karen JB, Jeffrey DB, Lisa AE, Elizabeth H, James PH, Sherry M, Wolfgang S, Meir S, Jane T, Elizabeth Y. Strategies and methods for research on sex differences in brain and behavior. *Endocrinology*. 2005;146:1650–1673.
55. Wizemann TM, Pardue ML. *Exploring the Biological Contributions to Human Health: Does Sex Matter?* Washington, DC: Board on Health Sciences Policy, Institute of Medicine; 2001.
56. Duarte MN, Paula MA, Rui AC, Rodrigo AC. Caffeine Consumption Prevents Diabetes-Induced Memory Impairment and Synaptotoxicity in the Hippocampus of NON-cZNO10/LTJ Mice. *Neurochem Int*. 2006;48:144.
57. Han BG, Hao CM, Tchekneva EE. Markers of glycemic control in the mouse: Comparisons of 6-h and overnight-fasted blood glucoses to HbA1c. *Am J Physiol Endocrinol Metab*. 2008;295:981–986.
58. Akagawa K, Tsukada Y. Presence and characteristics of catecholamine-sensitive Na-K ATPase in rat striatum. *J Neurochem*. 1979;32:269–271.
59. Fiske CH and Subbarow Y. The colorimetric determination of phosphorus. *J Biol Chem*. 1925;66:375.
60. Lowry OH, Rosenborough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem*. 1951;193:265–275.
61. Urzua Z, Rujillo XT, Uerta MH, Rujillo-Hernandez BT, Rios-Silva MR, Onetti CO, Ortis-Mesina M, Sanchez

- Pastor E. Effects of Chronic Caffeine Administration on blood glucose level and on glucose tolerance in healthy and diabetic rats. *J Int Med Res.* 2012;40:2220–2230.
62. Hadi B, Vahid ZK, Gholam AL. Glucose and Blood Lactate Levels Change after Caffeine Supplementation during 1-km and 20-km of cycling. *Ann Biol Res.* 2013;4:190–193.
63. Rob MV, Wilrike JP, Petra V. Effects of Coffee Consumption on Fasting Blood Glucose and Insulin Concentrations. Randomized controlled trials in healthy volunteers. *Diabetes Care.* 2004;12:2990–2992.
64. Jarbas SR, Ticiana MS, Idiane R, Ana LC, Antonio CS, Márcia LFC, Júlio CM, Matheus R. (Pre) diabetes, brain aging, and cognition. *Biochim Biophys Acta.* 2009;1792:432–443.
65. Oner P, Oztaş B, Koçak H. Brain cortex Na^+ - K^+ ATPase activities in streptozotocin-diabetic and pentylenetetrazol-epileptic rats. *Pharm Res.* 1997;36:69–72.
66. Stojanovic T, Djuricic BM, Mrsulja BB. The effect of physostigmine on Na^+ - K^+ ATPase activity in different rat brain regions. *Experientia.* 1980;36:1348–1350.
67. Naiara S, Roberta S, Luciane BP, Maribel AR, João BT, Graziela F, Maria EP, Cinthia MM, Sabina P, Marília VR, Fabiano BC, Michelle M, Jessie MG, Andréia MC, Vera MM, Maria RCS. Effects of chlorogenic acid, caffeine, and coffee on behavioral and biochemical parameters of diabetic rats. *Mol Cell Biochem.* 2013;388:277–286.
68. Graham E, Mishra OP, Deliviora-Papadopoulos M. Brain cell membrane Na^+/K^+ -ATPase modification following hypoxia in guinea pig fetus. *Neurosci Lett.* 1993;153:93.
69. Pernur O, Baria O, Hikmet K. Brain Cortex Na^+ - K^+ atpase activities in Streptozotocin-diabetic and Pentylenetetrazol-epileptic rats. *Pharm Res.* 1997;36:1.
70. Obochi GO, Abara AE, Malu SP, Obi-Abang M, Edu FE, Eteng MU, Umoh IB. Effect of Alcohol and Kolanut Interaction on Brain Sodium Pump Activity in Wistar Albino Rats. *Niger J Physiol Sci.* 2007;22:99–104.

Address correspondence to:

Aminat Omolola Imām-Fulani, BSc, MSc
Department of Physiology
University of Ilorin
Ilorin 23401
Nigeria

E-mail: faminat2@gmail.com